Evidence map›Paper›PMID 31250987›Full record

ArticleCancer medicine2019

Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p.

Lingling Tong, Yu Ao, Hejia Zhang, Kun Wang, Yunyun Wang, Qingjie Ma

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lingling TongDepartment of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, China.
Yu AoDepartment of Pediatric Intensive Care Unit (PICU), The First Hospital of Jilin University, Changchun, China.
Hejia ZhangDepartment of Ultrasonography, China-Japan Union Hospital of Jilin University, Changchun, China.
Kun WangDepartment of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, China.
Yunyun WangDepartment of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchun, China.
Qingjie MaDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, China.ORCID 0000-0002-2164-9955
Union Hospital · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn the present study, we evaluated the expression and function of human long noncoding RNA (lncRNA) activated by DNA damage (NORAD) in human epithelial ovarian cancer (EOC).

methodsNORAD expression was evaluated by qRT-PCR in EOC cell lines and in situ EOC clinical samples. Lentivirus-mediated NORAD downregulation was conducted in OVCAR-3 and ES-2 cells, and its effect on cancer cell proliferation, bufalin chemoresistance, cell-cycle transition in vitro, and xenotransplantation in vivo were examined, respectively. The likelihood of an lncRNA-microRNA (miRNA) signaling pathway was examined by probing the possible downstream competing target of NORAD, hsa-miR-155-5p. Moreover, hsa-miR-155-5p was knocked down in NORAD-downregulated EOC cells to functionally evaluate the correlation between NORAD and hsa-miR-155-5p in EOC.

resultsWe found that NORAD was substantially upregulated in both EOC cell lines and human tumors. In OVCAR-3 and ES-2 cells, lentivirus-mediated NORAD downregulation had significant anticancer effects, as it suppressed cell proliferation, decreased bufalin chemoresistance, arrested cell-cycle transition, and inhibited xenograft growth. Also, hsa-miR-155-5p was confirmed to be the competing target of NORAD in EOC, and its knockdown in OVCAR-3 and ES-2 cells reversed the NORAD downregulation-induced anticancer functions.

conclusionsNORAD is upregulated in EOC. Inhibition of NORAD, possibly through endogenously competing against hsa-miR-155-5p, can be a new tumor-suppressing strategy in EOC.

Indexed as

Up-RegulationAnimalsBufanolidesCarcinoma, Ovarian EpithelialCell Line, TumorCell ProliferationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMiceMicroRNAsNeoplasm TransplantationOvarian NeoplasmsRNA, Long NoncodingbufalinBufanolidesMicroRNAsMIRN155 microRNA, humanNORAD long non-coding RNA, humanRNA, Long Noncodingepithelial ovarian cancerhsa-miR-155-5plncRNAmiRNANORAD

Identifiers

PMID31250987
PMCPMC6712470
OpenAlexW2954315756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.